key: cord-0066041-llunu147
authors: Byrne, Eimear M.; Llorián-Salvador, María; Tang, Miao; Margariti, Andriana; Chen, Mei; Xu, Heping
title: IL-17A Damages the Blood–Retinal Barrier through Activating the Janus Kinase 1 Pathway
date: 2021-07-16
journal: Biomedicines
DOI: 10.3390/biomedicines9070831
sha: 8efda21a3074865a7c3f4a728dcb2b4c64b6393f
doc_id: 66041
cord_uid: llunu147

Blood–retinal barrier (BRB) dysfunction underlies macular oedema in many sight-threatening conditions, including diabetic macular oedema, neovascular age-related macular degeneration and uveoretinitis. Inflammation plays an important role in BRB dysfunction. This study aimed to understand the role of the inflammatory cytokine IL-17A in BRB dysfunction and the mechanism involved. Human retinal pigment epithelial (RPE) cell line ARPE19 and murine brain endothelial line bEnd.3 were cultured on transwell membranes to model the outer BRB and inner BRB, respectively. IL-17A treatment (3 days in bEnd.3 cells and 6 days in ARPE19 cells) disrupted the distribution of claudin-5 in bEnd.3 cells and ZO-1 in ARPE19 cells, reduced the transepithelial/transendothelial electrical resistance (TEER) and increased permeability to FITC-tracers in vitro. Intravitreal (20 ng/1 μL/eye) or intravenous (20 ng/g) injection of recombinant IL-17A induced retinal albumin leakage within 48 h in C57BL/6J mice. Mechanistically, IL-17A induced Janus kinase 1 (JAK1) phosphorylation in bEnd.3 but not ARPE19 cells. Blocking JAK1 with Tofacitinib prevented IL-17A-mediated claudin-5 dysmorphia in bEnd.3 cells and reduced albumin leakage in IL-17A-treated mice. Our results suggest that IL-17A can damage the BRB through the activating the JAK1 signaling pathway, and targeting this pathway may be a novel approach to treat inflammation-induced macular oedema.

The blood-retinal barrier (BRB) segregates the neuroretina from the periphery, thereby protecting the retina from exogenous pathogen invasion and systemic inflammatory disturbances. The BRB consists of the inner BRB (iBRB), i.e., tight junctions between retinal endothelial cells and outer BRB (oBRB), i.e., tight junctions between retinal pigment epithelial (RPE) cells. BRB dysfunction may result in the infiltration of circulating immune cells and the leakage of fluid into the neuroretina, causing retinal oedema. When oedema occurs in the macula (known as macular oedema), it can severely damage visual function. BRB dysfunction underpins many sight-threatening retinal diseases, such as diabetic macular oedema (DMO) [1] , age-related macular degeneration (AMD) [2, 3] and uveitis [4, 5] .

The mechanisms underpinning BRB dysfunction are complicated and incompletely understood. Inflammation is known to play an important role, and intravitreal injection of steroids, such as triamcinolone [6] [7] [8] [9] and intravitreal steroid implants (e.g., Ozurdex [10] and Retisert [11] [12] [13] ), has proven to be effective in controlling macular oedema caused by diabetic retinopathy (DR) or uveitis. However, these therapies often cause severe adverse effects, such as steroid-induced glaucoma and cataract [14] [15] [16] . Abnormal levels of vascular endothelial growth factor (VEGF) critically contribute to BRB leakage [17] , and intravitreal injection of VEGF inhibitors (e.g., anti-VEGF neutralizing antibodies) is the standard of care for macular oedema in various conditions (e.g., DR, neovascular was sufficient for tight junction dysmorphia and barrier dysfunction [48] . Then 30 min treatment with the same dose was used to examine JAK1 phosphorylation in response to IL-17A.

The bEnd.3 cells were treated with murine recombinant IL-17A (R&D Systems, Catalog No. 7956-ML-025/CF), at a concentration of 100 ng/mL. Three days of treatment with 100 ng/mL IL-17A was sufficient for tight junction dysmorphia and barrier dysfunction [49] . Thirty minutes of treatment with the same dose was used to examine JAK1 phosphorylation in response to IL-17A. Tofacitinib Citrate (Catalogue No. PZ0017, Sigma-Aldrich, St. Louis, MO, USA) (25 mg) was dissolved in 100 µL DMSO and further diluted in PBS, immediately before use, to 2.5 ug/mL (4.955 µM). Vehicle control for Tofacitinib was DMSO diluted 1:100,000 in PBS, i.e., 0.00001% DMSO.

Cell viability was assessed by using AlamarBlue™ Cell Viability Reagent (Thermo Fisher, Catalog No. DAL1100, Thermo Fisher, Waltham, MA, USA). Cells were regularly screened for mycoplasma, using LookOut ® Mycoplasma PCR Detection Kit (Catalog No. MP0035, Sigma-Aldrich).

The effects of IL-17A on TEER of both bEnd. 3 [48] and bEnd.3 [50] as described previously, following IL-17A treatment. Then 200 µL FITC-Dextran or FITC-Na (1 mg/mL) diluted in media was added to the apical chamber of transwell inserts. Fluorescence intensity of apical and basal chambers were measured at 495-570 nm by using a POLARstar Omega plate reader (BMG Labtech, Baden-Wurttemgerg, Germany). FITC concentrations were interpolated from the standard curve. Diffusion rate calculation was adapted from a previously published formula [48] .

Diffusion rate (%) = (FITC concentration in basal chamber × 100)/(FITC concentration in apical chamber)

Following IL-17A treatment, with or without Tofacitinib Citrate, ARPE-19 and bEnd.3 cells were stained for rabbit anti-ZO-1 and rabbit anti-claudin-5, respectively, to examine tight junction alterations. Both cell types were stained with Rabbit Phospho-JAK1 (Tyr1034, Tyr1035) antibody to examine JAK1 phosphorylation, following IL-17A treatment. All the above antibodies were from Thermo Fisher. Antibody details are shown in the Table 1 .

C57BL6/J mice aged 2 months old, of both sexes, were used for these studies; n ≥ 5 animals were assigned per experimental group. Mice were maintained in the Biological Services Unit at Queen's University Belfast, with free access to food and water on a 12 h light/dark cycle, in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. All procedures were approved by the UK Home Office Animals (Scientific Procedures) Act 1986 and the local animal welfare ethical review board of Queen's University Belfast (DOH PPL2876). 

Two-month-old C57BL/6J mice were injected intravitreally (ivt, 20 ng/µL/eye, n = 20 mice animals per group) or intravenously (i.v. 20 ng/g, n = 6 animals per group) with murine recombinant IL-17A (R&D Systems). Forty-eight hours after, animals were subjected to Micron IV examination, and eyes were collected for immunostaining or retinal protein was extracted for Western blot (see details below). For Tofacitinib Citrate treatment, 2-month-old C57BL6/J mice were treated with Tofacitinib Citrate (15 mg/kg, i.p.) immediately after IL-17A i.v. injection. Tofacitinib Citrate was administered again 24 h later, and mice were culled at 48 h (Appendix A Figure 1 ). Eyes were processed for Western blot for albumin (marker of BRB leakage) and immunostaining for pJAK1 and albumin.

Mouse pupils were dilated by using atropine (1% w/v) and phenylephrine hydrochloride (2.5% w/v) (Bausch + Lomb, address United Kingdom), and the ocular surface was moistened with Viscotears (Novartis Pharmaceuticals Ltd., Surrey, UK). Mice were anaesthetized with ketamine hydrochloride (60 mg/kg, Fort George Animal Centre, Southampton, UK) and xylazine (5 mg/kg, Pharmacia & Veterinary Products, Kiel, Germany) via intraperitoneal injection. Fundus fluorescence angiography images FFA images were taken 2 min after intravenous injection of 100 µL of 1 mg/mL 4kDa FITC-Dextran, using Micron IV (Phoenix Technology Group, Pleasanton, CA, USA).

Paraffin-embedded eyes were sectioned at 5 µm thickness. De-waxing was carried out by immersing slides in 3 changes of clearene for 5 min each, followed by 3 changes of 100% ethanol for 3 min each, and followed by 5 min in running water. Citraconic anhydride (Sigma, Catalog No. 125318), pH 7.4, at 95 • C, for 30 min, was used for antigen retrieval. Slides were incubated with goat anti-albumin and Biotinylated Griffonia Simplicifolia Lectin I Isolectin B4 (Table 1) , overnight, at 4 • C. The next day, slides were washed in PBS prior to incubation with appropriate secondary antibodies. Slides were mounted with DAPI-Vectashield and imaged by using a Leica DMi8 epifluorescence microscope. Images were analyzed by using FIJI (NIH); Isolectin B4-positive ROIs were restored on the albumin channel and measured prior to whole neuroretina measurements. Leakage ratio was calculated as follows:

Leakage Ratio = (Extravascular albumin)/(Total albumin in neuroretina)

Paraffin-embedded eyes were treated as above. After blocking, pJAK1 antibody was applied at a concentration of 1:100, at 4 • C, overnight. After several washes, secondary antibody donkey anti-rabbit 594 (Stratech Scientific Ltd, Ely, UK) was applied at 1:300 for 2 h. Slides were washed, mounted with DAPI-vectashield and imaged as above. Then pJAK1 in the neuroretina was quantified by using FIJI.

Samples were homogenized in RIPA buffer containing protease inhibitor cocktail (Sigma) and PhosSTOP™ (Roche). Protein concentrations were normalized by using Pierce BCA protein assay kit (Thermo Fisher, Catalog# 23225). Protein samples of equal concentrations were denatured by using NuPAGE™ 10X Reducer and LDS Sample Buffer (4X) (Thermo Fisher, Catalog No. NP0004, NP0007) as per the manufacturer's instructions. Then 10 µg (retinal protein for albumin detection) or 35 µg (cell protein for phospho-JAK1 detection) was loaded on 10% acrylamide gels. Proteins were transferred to PVDF membranes (Immun-Blot, Bio-Rad Laboratory, Hercules, CA, USA), using the wet transfer method. Membranes were blocked with 5% Bovine Serum Albumin (Sigma-Aldrich, Catalog No. A3803) for 1 h, before primary antibody incubation overnight. The next day, membranes were washed, incubated in appropriate secondary antibody washed and developed by using Clarity Western ECL Blotting Substrate (Bio-Rad, Catalog No. 1705061). Membranes were imaged by using G:BOX Chemi XRQ chemiluminescence imager (Syngene, Cambridge, UK). Secondary antibody probing was used to confirm successful stripping. Densitometry was analyzed by using FIJI software.

Graph generation and statistical analyses were performed by using GraphPad Prism 9 (GraphPad Software Inc. San Diego, CA, USA). The differences between two groups were compared by using unpaired t-test. For the difference between three or more groups, we used One-Way ANOVA, followed by Tukey's (to compare the means of each groups with the means of every other group) or Dunnett's (to compare the means of each treatment group with the mean on of the control group) multiple comparison post hoc tests.

Claudin-5 junctions are integral to endothelial cell tight junctions. Under normal culture conditions, claudin-5 was evenly distributed around the cell-cell junction of bEnd3 cells ( Figure 1A ). IL-17A treatment (72 h) induced fragmented and clustered claudin-5 expression in bEnd.3 cells (arrowheads, Figure 1A ). Measurement of trans-epithelial electrical resistance (TEER) in bEnd3 cells cultured in the transwell membrane showed that 72 h of treatment with IL-17A significantly reduced TEER ( Figure 1B ). FITC-Na permeability showed a pattern indicative of leakage, but was not statistically significant in IL-17A-treated bEnd3 cells ( Figure 1C) .

A previous study reported ZO-1 junction dysmorphia in ARPE-19 cells following 6 days of IL-17A treatment [48] . This was confirmed in our study ( Figure 1D ). Six days of IL-17A treatment induced fragmented ZO-1 junctions and positive staining in the cytosol and nuclei in ARPE-19 cells (arrows, Figure 1D ). The treatment also significantly reduced TEER ( Figure 1E ) and increased FITC-Dextran (4 kDa) permeability ( Figure 1F ) in ARPE19 cells cultured in transwell membranes. Together, these data suggest that IL-17A alone can induce both vascular endothelial cell (iBRB) and retinal pigment epithelial cell (oBRB) dysfunction in vitro.

Wild-type C57BL/6J mice received IL-17A (ivt, 20 ng/µL/eye) or (i.v., 20 ng/g), and BRB function was examined 48 h later. Western blot showed significantly higher levels of albumin in the retinae from IL-17A ivt treated mice compared to mice that received no injection (NI) (Figure 2A) . Retinal section immunostaining also showed higher levels of albumin expression in IL-17A ivt mice ( Figure 2B ). Micron IV examination revealed FITC-Dextran (4 kDa) extravasation in mice received IL-17A ivt injection compared to control PBS ivt mice (arrows, Figure 2C ). 

To understand the signaling pathways involved in IL-17A-induced BRB damage, we investigated the JAK/STAT pathway, as it is a master regulator of cytokine receptor signaling. As the commercially available JAK/STAT array kit was only for human tissues, we conducted a human JAK/STAT array assay in IL-17A-treated ARPE19 cells. The results show that 30 min treatment with IL-17A increased the expression of SHP1, pJAK1, pTYK2 and pSTAT6 in ARPE19 cells (Appendix A Figure A2 ). Further Western blot and immunocytochemistry showed that IL-17A treatment significantly upregulated pJAK1 expression in bEnd.3 cells (Figure 3A -C) but not in ARPE19 cells (Appendix A Figure 3 ). However, pSTAT3 expression was increased in IL-17A-treated ARPE19 cells (Appendix A Figure A4 ). As IL-6 and VEGF can also active the JAK/STAT pathway, we measured their concentrations in the supernatants from control and IL-17A-treated bEnd.3 cells. We found that the 3-6 days of IL-17A treatment appeared to upregulate IL-6, but not VEGFA production (Appendix A Figure A5) .

Injection (i.v.) of IL-17A upregulated pJAK1 expression in mouse retina, particularly the inner layers (ganglion cell layer and inner plexiform layer, Figure 3D ). The location of pJAK1 positivity in the inner retina and the fact that in vitro treatment of ARPE19 cells (oBRB) with IL-17A did not seem to increase pJAK1 expression (Figure 3 ) led us to focus our study on the role of JAK1 in IL-17A-mediated iBRB damage, rather than oBRB damage.

To further explore the role of JAK1 activation in IL-17A-mediated iBRB dysfunction, we tested the effect of a JAK1/3 inhibitor Tofacitinib Citrate in the in vitro model of iBRB, i.e., bEnd.3 cultured in transwell membrane ( Figure 4A ). Tofacitinib Citrate did not affect bEnd.3 cell viability at or below 4.955 µM (Appendix A Figure A6 ). Pretreatment of iBRB with Tofacitinib (4.955 µM) for 30 min significantly prevented IL-17A-mediated TEER reduction ( Figure 4B ) and preserved claudin-5 expression ( Figure 4C ). 

Having shown that i.v. injection of IL-17A upregulated pJAK1 expression in mouse retina ( Figure 3A) , we moved to investigate if the upregulation of pJAK1 could be reduced by JAK1/3 inhibitor Tofacitinib Citrate. IL-17A-or vehicle-injected mice were administered with Tofacitinib Citrate (15 mg/kg) once a day, for two days, and retinal pJAK1 expression was evaluated 48 h later ( Figure 5A ). The results confirmed the upregulation of pJAK1 by IL-17A ( Figure 5B,C) , Similar levels of pJAK1 expression were present in IL-17A and IL-17A+vehicle groups. Tofacitinib Citrate treatment slightly reduced IL-17A-mediated retinal pJAK1 expression; however, the reduction did not reach statistical significance ( Figure 5C ), which may be related to the large variation and insufficient sample size.

To understand the functional role of JAK1 activation in IL-17A-mediated iBRB dysfunction, mice were treated with Tofacitinib immediately after IL-17A injection, and again 24 h later ( Figure 6A ). Retinal vascular leakage was evaluated 48 h later by immunostaining of al-bumin. Extravascular albumin was successfully reduced in Tofacitinib Citrate-treated animals compared to those treated with vehicle control and IL-17A, or IL-17A alone ( Figure 6B,C) , indicating that JAK1 is functionally involved in iBRB leakage in IL-17A-induced BRB dysfunction. Values were normalized to PBS control on the same slide. Mean ± SD. ROUT outliers test 2% was used to remove outliers. Cleaned data were compared by using One-Way ANOVA with Tukey's multiple comparisons test, * p < 0.05; ns: no statistical significance. Values were normalized to PBS control on the same slide. Mean ± SD; n ≥ 5 animals per group; ROUT outliers test 2% was used to remove outliers. Cleaned data were compared by using One-Way ANOVA with Tukey's multiple comparisons test, * p < 0.05; ns: no statistical significance.

In this study, we showed that IL-17A can induce BRB dysfunction both in vitro and in vivo. Mechanistically, IL-17A damages the structure of tight junctions in both endothelial and RPE cells. In endothelial cells, the barrier destructive effect of IL-17A was mediated by activating the JAK1 signaling pathway. We further found that the JAK1 antagonist Tofacitinib Citrate could effectively ameliorate IL-17A-mediated BRB leakage. Tofacitinib is an FDA-approved anti-inflammatory medication, used to treat autoimmune diseases such as rheumatoid arthritis [49] and ulcerative colitis [51] [52] [53] . Our results suggest that Tofacitinib or other JAK1 inhibitors may be re-purposed for the management of IL-17A mediated macular oedema.

IL-17A is produced predominantly by CD4 + Th17 cells in response to cytokine IL-23 [54] [55] [56] and plays an important role in various autoimmune diseases, including uveitis [43, 46, 57] . Some innate immune cells, such as neutrophils [58] [59] [60] and γδT cells [61, 62] , can also produce IL-17A. In addition to its role in activating various immune cells, IL-17A is also reported to be involved in barrier dysfunction, including the blood-brain barrier [63] . In the retina, IL-17A is known to be involved in the pathogenesis of autoimmune uveitis [41] [42] [43] 64] , AMD [40, [46] [47] [48] [65] [66] [67] [68] and DR [35] [36] [37] [38] 69] . Higher levels of IL-17A have been detected in the vitreous fluid of DMO patients [44, 69] , PDR patients [44, 70] , in AMD lesions [47] and in the serum of uveitis patients [42] . We found that both intravitreal and intravenous administration of IL-17A-induced BRB leakage, suggesting that IL-17A may damage the BRB from both the luminal and abluminal sides. The abnormal serum levels of IL-17A and intraocular IL-17A may all contribute to vascular leakage and macular oedema in patients with DMO, PDR, AMD and other retinal vascular diseases.

This study provides novel evidence of IL-17A-mediated pJAK1 activation in iBRB cells (vascular endothelial cells) and the murine retina. The signal transduction of sev-eral cytokines, including IL-17A, IL-6 and VEGF, have been reported to converge in the JAK/STAT pathway [71, 72] . We found that 3-6 days of treatment with IL-17A could increase IL-6 but not VEGF production in bEnd.3 cells, indicating that IL-17A can active the JAK/STAT pathway directly and indirectly under chronic disease conditions, such as in DR and uveoretinitis. Many reports have delineated the role of the JAK/STAT pathway in retinal diseases involving BRB dysfunction, namely in DR [73, 74] , AMD [75, 76] and uveoretinitis [77, 78] . This finding is in agreement with studies which showed that Tofacitinib Citrate is effective in refractory anterior and intermediate uveitis and scleritis [79, 80] and with another study, which showed it is protective against cytokine-mediated barrier dysfunction in the gastrointestinal tract [81] . Therefore, targeting the JAK/STAT pathway is a strategy that is worthy of exploration for the management of retinal diseases involving BRB dysfunction.

The limitations of our study include the use of cell lines ARPE-19 as oBRB and bEnd.3 as iBRB models, and that these models do not take into account of the effect of other supporting cells in the neurovascular unit, such as pericytes and Muller cells. Previous studies have shown that IL-17A can activate pericytes in vitro [82] through IL-17RA/C and induce endothelial basement membrane remodeling [83] . Future studies using primary or iPS-derived RPE or retinal endothelial cells together with pericytes and/or Muller cells in 3D culture models will be helpful to better understand the mechanism of IL-17A-induced BRB damage.

Our results suggest that IL-17A can damage the BRB through activation of the JAK1 signaling pathway. Since JAK1 is also involved in the signal transduction of other barrierdamaging cytokines, such as IL-6 and VEGF, targeting this pathway may be a novel approach for the management of macular oedema, particularly those who are resistant to anti-VEGF therapy. 

The data presented in this study are all contained within the main body of this article.

The authors thank Eszter Emri, Jose Romero, Peter Barabas and Joana Sa Pessoa for helpful discussions during this project. The authors acknowledge the BSU at Queen's University Belfast for their assistance in animal maintenance.

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. 

Diabetic Macular Edema: Pathogenesis and Treatment

Inner blood-retina barrier involvement in dry age-related macular degeneration (AMD) pathology

Blood-retinal barrier as a converging pivot in understanding the initiation and development of retinal diseases

Leukocyte trafficking in experimental autoimmune uveitis: Breakdown of blood-retinal barrier and upregulation of cellular adhesion molecules

Bowman lecture on the role of inflammation in degenerative disease of the eye

Treatment of Acute Posterior Uveitis in a Porcine Model by Injection of Triamcinolone Acetonide into the Suprachoroidal Space Using Microneedles

Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

Current treatments in diabetic macular oedema: Systematic review and meta-analysis

Update on corticosteroids for diabetic macular edema

Intravitreal dexamethasone implant Ozurdex ® in naïve and refractory patients with different subtypes of diabetic macular edema

Fluocinolone acetonide intravitreal implant (Retisert ® ) in the treatment of sight threatening macular oedema of juvenile idiopathic arthritis-related uveitis

A New Approach for Diabetic Macular Edema Treatment: Review of clinical practice results with 0.19 mg fluocinolone acetonide intravitreal implant including vitrectomized eyes

Fluocinolone acetonide for the treatment of diabetic macular edema

Steroid-induced Glaucoma: An Avoidable Irreversible Blindness

Elevated Intraocular Pressure After Intravitreal Steroid Injection in Diabetic Macular Edema: Monitoring and Management

Corticosteroid-induced glaucoma: A review of the literature

Vascular Endothelial Growth Factor A in Intraocular Vascular Disease

Anti-vascular endothelial growth factor for diabetic macular oedema: A network meta-analysis

Effect of Intravitreal Anti-Vascular Growth Factor Agents with or Without Macular Photocoagulation on Diabetic Macular Edema: A Systematic Review and Meta-Analysis

Therapeutic Options in Refractory Diabetic Macular Oedema

Treatment choices for diabetic macular oedema: A guideline for when to consider an intravitreal corticosteroid, including adaptations for the COVID-19 era

Microaneurysm density in residual oedema after anti-vascular endothelial growth factor therapy for diabetic macular oedema

Sustained intraocular VEGF neutralization results in retinal neurodegeneration in the Ins2Akita diabetic mouse

Is an Autocrine Gliotrophic Factor for Müller Cells under Pathologic Conditions

Relationships Between Neurodegeneration and Vascular Damage in Diabetic Retinopathy

-17A, and TNF-α in Aqueous Humour of Patients with Diabetic Retinopathy

Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with Bevacizumab

Aqueous Humor Cytokine Levels in Diabetic Macular Edema Patients with Cotton-Wool Spots

The Interplay Between Systemic Inflammatory Factors and MicroRNAs in Age-Related Macular Degeneration

Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy

Cytokine profiling reveals increased serum inflammatory cytokines in idiopathic choroidal neovascularization

Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation

Neutralization of interleukin-17A alleviates burn-induced intestinal barrier disruption via reducing pro-inflammatory cytokines in a mouse model

IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis

Diabetes-mediated IL-17A enhances retinal inflammation, oxidative stress, and vascular permeability

Effect of the blockade of the IL-23-Th17-IL-17A pathway on streptozotocin-induced diabetic retinopathy in rats. Graefe's Arch

Blocking IL-17A Alleviates Diabetic Retinopathy in Rodents

IL-17A exacerbates diabetic retinopathy by impairing Müller cell function via Act1 signaling

Genetic Variants of Interleukin 17A Are Functionally Associated with Increased Risk of Age-Related Macular Degeneration

A role for IL-17 in age-related macular degeneration

Regulatory T cells and IL-17A levels in noninfectious uveitis. Graefe's Arch

Elevated Serum Levels of Interleukin-17A in Uveitis Patients

Neutralization of IL-17 ameliorates uveitis but damages photoreceptors in a murine model of spondyloarthritis

Th17 cell frequency and IL-17A concentrations in peripheral blood mononuclear cells and vitreous fluid from patients with diabetic retinopathy

Differential roles for IFN-and IL-17 in experimental autoimmune uveoretinitis

Complement component C5a Promotes Expression of IL-22 and IL-17 from Human T cells and its Implication in Age-related Macular Degeneration

Interleukin-17 Retinotoxicity Is Prevented by Gene Transfer of a Soluble Interleukin-17 Receptor Acting as a Cytokine Blocker: Implications for Age-Related Macular Degeneration

The Effects of Th17 Cytokines on the Inflammatory Mediator Production and Barrier Function of ARPE-19 Cells

Cellular mechanisms of IL-17-induced blood-brain barrier disruption

Paracellular Barrier and Tight Junction Protein Expression in the Immortalized Brain Endothelial Cell Lines bEND.3, bEND.5 and Mouse Brain Endothelial Cell 4

The mechanism of action of tofacitinib-An oral Janus kinase inhibitor for the treatment of rheumatoid arthritis

JAK inhibition using tofacitinib for inflammatory bowel disease treatment: A hub for multiple inflammatory cytokines

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis

Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases

The IL-23/IL-17 axis in inflammation

Suppression of Experimental Autoimmune Uveoretinitis by Anti-IL-17 Antibody

IL-17 produced by neutrophils regulates IFN-γ-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury

IL-17A) in a Dectin-1-and IL-23-Dependent Manner during Invasive Fungal Infection

Neutrophils Are Essential as A Source Of Il-17 In The Effector Phase Of Arthritis

Interleukin-17-producing γδ T (γδ17) cells in inflammatory diseases

IL-17-producing γδ T cells

Chronic Inflammatory Neurological Diseases. Front. Immunol. 2020, 11, 947

Roles of interleukin-17 in uveitis

Increased Th1/Th17 Responses Contribute to Low-Grade Inflammation in Age-Related Macular Degeneration

Inflammatory Mechanisms of Age-related Macular Degeneration

Molecular pathology of macrophages and interleukin-17 in age-related macular degeneration

Interleukin-17: The Role for Pathological Angiogenesis in Ocular Neovascular Diseases

Interleukin-17A deficiency ameliorates streptozotocin-induced diabetes

Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy

IL-17 induces reactive astrocytes and up-regulation of vascular endothelial growth factor (VEGF) through JAK/STAT signaling

Interleukin-17 upregulates vascular endothelial growth factor by activating the JAK/STAT pathway in nucleus pulposus cells

Endothelial STAT3 Activation Increases Vascular Leakage Through Downregulating Tight Junction Proteins: Implications for Diabetic Retinopathy

STAT3 activation in circulating myeloid-derived cells contributes to retinal microvascular dysfunction in diabetes

STAT3 Activation in Circulating Monocytes Contributes to Neovascular Age-Related Macular Degeneration

Hyperglycaemia Exacerbates Choroidal Neovascularisation in Mice via the Oxidative Stress-Induced Activation of STAT3 Signalling in RPE Cells

SOCS3 deletion in myeloid cells worsens retinal inflammation and increases angiogenesis in experimental autoimmune uveoretinitis

Cytokine Signaling Protein 3 Deficiency in Myeloid Cells Promotes Retinal Degeneration and Angiogenesis through Arginase-1 Up-Regulation in Experimental Autoimmune Uveoretinitis

JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis

Tofacitinib for refractory uveitis and scleritis

The JAK-Inhibitor Tofacitinib Rescues Human Intestinal Epithelial Cells and Colonoids from Cytokine-Induced Barrier Dysfunction

IL-17 Promotes Neutrophil-Mediated Immunity by Activating Microvascular Pericytes and Not Endothelium

Tumor Necrosis Factor-α and IL-17A Activation Induces Pericyte-Mediated Basement Membrane Remodeling in Human Neutrophilic Dermatoses